The life sciences consulting market is experiencing unprecedented M&A activity, driven by private equity-backed consolidation and the rapid expansion of advanced therapeutics, AI, and digital transformation.
With nearly 80% of transactions led by PE investors, firms are actively scaling through acquisitions to enhance regulatory, clinical, and commercialization capabilities. Deal valuations remain strong, reflecting the premium placed on niche expertise and innovation.